Photo Release — Pacific Biosciences Launches the PacBio(R) RS II Sequencing System
Thursday, April 11, 2013
A photo accompanying this release is available at https://www.globenewswire.com/newsroom/prs/?pkgid=18068
The PacBio RS II allows scientists to rapidly and cost effectively generate finished genome assemblies, reveal and understand epigenomes, and characterize genomic variation. Based on the company’s revolutionary SMRT Sequencing technology, the RS II can generate average read lengths of 5,000 base pairs, with the longest reads above 20,000 base pairs in length. The PacBio RS II System, including consumables and software, provides a simple, fast, end-to-end workflow for SMRT Sequencing in research areas including infectious disease and microbiology, agriculture, and complex genetic diseases with repeat expansions.
With the PacBio RS II, the number of simultaneously observable sequencing reactions is doubled, which effectively doubles the throughput of the system. This increase in the number of reads will drive new applications such as full-length cDNA analysis and full-length 16S metagenomics. The PacBio RS II features PacBio’s C2 and XL chemistries, new analysis software with automated de novo assembly, and other improvements released in the past two years, including: increased consensus accuracy to greater than 99.999% (Q50), a quadrupling of average
read lengths, and a 10-fold reduction in input DNA required.
“In addition to providing more, high-quality data in a highly robust system, the PacBio RS II includes all of the performance improvements we have made since we launched the commercial PacBio RS System in 2011,” said
Customers with existing PacBio RS Systems can purchase an upgrade, which will convert the PacBio RS to the new PacBio RS II. Installations of the new PacBio RS II System are expected to begin in the second quarter of 2013. For more information please visit www.pacb.com/rsII.
About Pacific Biosciences
The photo is also available via AP PhotoExpress.
Maurissa MessierFor Pacific Biosciences 760.539.7417 email@example.com Investors: Trevin RardPacific Biosciences 650.521.8450 firstname.lastname@example.org
News Provided by Acquire Media